Drug Trial Radar · NCT07527858
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
170
Planned (sponsor's estimate)
Start
May 19, 2026
Primary completion
Dec 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Apr 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC). The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).
Conditions
- Advanced Microsatellite Stable Colorectal Cancer
Interventions
DenikitugDrug
Administered Intravenously
NivolumabDrug
Administered Intravenously
BevacizumabDrug
Administered Intravenously
Trifluridine-TipiracilDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Up to 60 months
Locations
15 sites in 4 countries. Site status is shown where the registry gives one.
Yale-New Haven Hospital - Yale Cancer Center
North Haven, Connecticut · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Active not recruiting
Washington University School of Medicine
St Louis, Missouri · Not yet recruiting
Avera Cancer Institute
Sioux Falls, South Dakota · Recruiting
University of Virginia,
Charlottesville, Virginia · Recruiting
Chris O'Brien Lifehouse
Camperdown, CA, Australia · Recruiting
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Recruiting
Royal North Shore Hospital
Saint Leonards, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Samsung Medical Center
Busan, South Korea · Not yet recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Yonsei University Severance Hospital ( aka Yonsei Cancer Center)
Seoul, South Korea · Not yet recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
Hospital General Universitario Gregorio Maranon
Madrid, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.